Equities research analysts at Morgan Stanley assumed coverage on shares of TherapeuticsMD Inc (NYSEMKT:TXMD) in a research note issued to investors on Friday, StockTargetPrices.com reports. The firm set an “equal weight” rating and a $6.00 price target on the specialty pharmaceutical company’s stock. Morgan Stanley’s target price suggests a potential downside of 13.17% from the company’s current price.

A number of other equities research analysts have also recently weighed in on TXMD. BidaskClub raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Friday. Oppenheimer Holdings Inc. raised shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a research note on Thursday, May 11th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $18.93.

TherapeuticsMD (NYSEMKT TXMD) traded down 0.58% during trading on Friday, hitting $6.87. 1,377,902 shares of the company were exchanged. The company’s market capitalization is $1.40 billion. The stock’s 50-day moving average is $5.83 and its 200-day moving average is $5.56. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30.

ILLEGAL ACTIVITY WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/08/therapeuticsmd-inc-txmd-receives-new-coverage-from-analysts-at-morgan-stanley.html.

Several institutional investors have recently made changes to their positions in the company. Norges Bank acquired a new position in shares of TherapeuticsMD in the 4th quarter valued at $8,261,000. WFG Advisors LP acquired a new position in shares of TherapeuticsMD in the 4th quarter valued at $204,000. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of TherapeuticsMD by 20.3% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 22,150 shares of the specialty pharmaceutical company’s stock valued at $128,000 after acquiring an additional 3,740 shares during the period. Guggenheim Capital LLC increased its holdings in shares of TherapeuticsMD by 135.9% in the 4th quarter. Guggenheim Capital LLC now owns 36,290 shares of the specialty pharmaceutical company’s stock valued at $209,000 after acquiring an additional 20,904 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in shares of TherapeuticsMD in the 4th quarter valued at $1,731,000.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Stock Target Prices

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.